S4 Shanghai–Jinshan Expressway

Asymchem and LaNova Medicines Enter into Partnership Agreement, Expanding Biological Capabilities

Retrieved on: 
Thursday, September 16, 2021
Cancer, R, S4 Shanghai–Jinshan Expressway, Efficiency, Drug development, Antibody, Control, G protein-coupled receptor, Patient, Blood, Contract, COO, CDMO, Breast, Solution, ADC, Multimedia, Brain, Partnership, Lung, Valerie Hobson, Fine chemical, Vaccine

The collaboration between Asymchem and LaNovawill include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.

Key Points: 
  • The collaboration between Asymchem and LaNovawill include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.
  • "In the future, we expect to build ADC pilot and commercial production facilities to further enhance Asymchem's capabilities with ADC drugs."
  • Based in Shanghai, LaNova Medicines is a clinical-stage R&D company whose primary focus is the development of macromolecular anti-tumor drugs utilizing GPCRs for monoclonal antibody production.
  • Neither Asymchem nor its subsidiaries assume an obligation to update the forecasts, expectations or statements contained in this release.